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Abstract
Although hypertension is a worldwide health issue, an incomplete understanding of its etiology 
has hindered our ability to treat this complex disease. Here we identify arhgap42 (also known as 
GRAF3) as a Rho-specific GAP expressed specifically in smooth muscle cells in mice and 
humans. We show that GRAF3-deficient mice exhibit significant hypertension and increased 
pressor responses to angiotensin II and endothelin-1; these effects are prevented by treatment with 
the Rho-kinase inhibitor, Y-27632. RhoA activity and myosin light chain phosphorylation are 
elevated in GRAF3-depleted smooth muscle cells in vitro and in vivo, and isolated vessel 
segments from GRAF3-deficient mice show increased contractility. Taken together our data 
indicate that GRAF3-mediated inhibition of RhoA activity in vascular smooth muscle cells is 
necessary for maintaining normal blood pressure homeostasis. Moreover, these findings provide a 
potential mechanism for a hypertensive locus recently identified within arhgap42 and provide a 
foundation for the future development of innovative hypertension therapies.
Introduction
Although hypertension is a major risk factor for stroke, myocardial infarction, and kidney 
failure, we know surprisingly little about the pathophysiology of its development. One 
reason for this is that blood pressure is a complex trait that is regulated by many organ 
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systems and a large number of humoral factors. Increased peripheral vascular resistance due 
to decreased arteriolar vessel diameter is a common feature of hypertension. This parameter 
is controlled, at least in part, by the contraction of vascular smooth muscle cells (SMC) 
within the resistance arterioles3-7 and many antihypertensive therapies inhibit the signaling 
pathways that control SMC contractility. In contrast to skeletal and cardiac muscle, 
excitation-contraction coupling in SMC is mediated by the Ca2+-dependent activation of 
myosin light chain kinase (MLCK), and SMC tension is directly proportional to myosin 
light chain (MLC) phosphorylation8,9. SMC contractility is also enhanced by activation of 
the small GTPase RhoA which leads to Rho-kinase (ROCK)-dependent inhibition of myosin 
phosphatase10-13.
Many GPCR-coupled contractile agonists including angiotensin II (AngII), norepinephrine, 
endothelin-1 (ET-1), stimulate RhoA in SMC, and several lines of evidence have implicated 
RhoA signaling in the development of hypertension. Increased ROCK activity has been 
observed in spontaneously hypertensive rats and some hypertensive patient populations10,14 
and ROCK inhibitors like Y-27632, Fasudil, and SAR407899 have been shown to reduced 
blood pressure in hypertensive animal models and patients15. Recent studies in genetically 
modified mice demonstrated that germline deletion of the Rho-specific guanine exchange 
factor (GEF), LARG, inhibited salt-induced hypertension16 while SMC-specific knockout of 
the related GEF, p115RhoGEF, inhibited the development of hypertension in response to 
AngII14. RhoA activity is limited by GAPs that facilitate RhoA's intrinsic GTPase activity, 
but little is known about the involvement of RhoGAPs in the regulation of SMC contractility 
or the development of hypertension.
Several recent Genome-Wide Association Studies (GWAS) have identified novel genetic 
polymorphisms that contribute to variations in blood pressure and other cardiovascular 
disease end-points17. Most of these are found within or near genes that have no known 
connection to the control of blood pressure, and a critical next step is to determine the 
mechanism by which they exert their effects. One such locus on chromosome 11 represented 
by SNPs rs633185 and rs604723 is within the 80KB first intron of FLJ328101,2. This gene, 
which was later annotated as arhgap42 (also known as GRAF3) is a member of the GRAF 
family of Rho-specific GAPs whose founding member, GRAF1, was originally described by 
our group18-20. While we showed that GRAF1 plays an important role in limiting RhoA 
activity in terminally differentiated cells (i.e. skeletal muscle, heart, and brain) no studies to 
date have explored the expression or function of GRAF319-21. Interestingly, our genome 
wide analyses of chromatin structure in primary human SMC by DNAse hypersensitivity 
identified several regions within the GRAF3 gene that were selectively “open” in SMC 
compared to over 25 other human cell types, suggesting that this gene was regulated in a 
smooth muscle-specific fashion (C.M., personal communication).
Given the known involvement of RhoA and RhoGEFs in the control of blood pressure, we 
hypothesized that GRAF3's association with blood pressure regulation was mediated by its 
ability to inhibit RhoA in SMC. Herein we validate GRAF3 as a Rho-specific GAP and 
show that it is strongly and specifically expressed in SMC. Importantly, we found that 
GRAF3-deficient mice are significantly hypertensive and exhibit Rho-kinase-dependent 
increases in contractile agonist-induced pressor responses. Collectively, these data indicate 
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that GRAF3-dependent inhibition of RhoA activity in vascular SMC is necessary for 
maintaining normal blood pressure homeostasis.
Results
GRAF3 is expressed in a smooth muscle-restricted fashion
Immunohistochemical analysis of mouse and human tissues with 2 distinct GRAF3 
antibodies that do not react with GRAF1 or GRAF2 (Supplementary Fig. S1a,b), revealed 
that GRAF3 was highly and selectively expressed in SMC (Fig. 1; Supplementary Fig. S1c; 
Supplementary Fig. S2d,e). As shown by co-staining with SM α-actin and PECAM, GRAF3 
expression was limited to the medial SMC layer in all vessels and to the SMC layers of the 
stomach, intestine, and lung. RT-PCR confirmed that GRAF3 RNA was highly abundant in 
primary SMC isolated from rodent aortae and in GI tissues that contain a large SMC 
component (see Figs. 2b, 4b; Supplementary Fig. S2b,c).
Development of GRAF3 hypomorphic mice
To explore GRAF3's role in regulating vessel tone and blood pressure homeostasis in vivo, 
we generated a GRAF3 deficient mouse line using ES cells that contained an inhibitory 
LacZ gene trap within the GRAF3 third intron (Fig. 2a and Supplementary Fig. S2a and 
Supplementary Table S1). Crosses between GRAF3+/gt mice yielded offspring in the 
appropriate Mendelian ratios, and no overt phenotypes were observed in GRAF3+/gt or 
GRAF3gt/gt mice for up to 6 months (Supplementary Table S2). GRAF3 message was 
strongly but not completely depleted in all tissues evaluated indicating that our gene trap 
model results in a hypomorphic allele (Fig. 2b, Supplementary Fig. S2c). Importantly, 
GRAF3 mRNA levels in the aorta and coronary vasculature were reduced by 80 and 99%, 
respectively and reductions in GRAF3 message were consistent in all tissues at all time 
points analyzed (between 2 and 16 weeks postnatal). Tissue-specific differences in residual 
GRAF3 mRNA levels in our model were likely due to the differential expression or activity 
of splicing factors22. Inclusion of the LacZ/neo insertion cassette into the GRAF3 transcript 
results in a heterologous protein that contains GRAF3 amino acids 1-104 fused in frame to 
the β-Gal reporter gene (Fig. 2a). As expected, β-Gal staining in gene trap mice closely 
mimicked endogenous GRAF3 expression with strong and selective staining within the 
heart, mesenteric, skeletal muscle, and brain arterioles and the SMC layers of the GI tract 
(Fig. 2c, Supplementary Fig. S2f). High power images co-stained with β-Gal and PECAM 
antibodies revealed that expression in the vasculature including coronary and renal vessels 
was restricted to SMC.
GRAF3 depletion elevates vessel tone and blood pressure
We evaluated blood pressure in 12-16 week old Wt and GRAF3gt/gt mice using 
radiotelemetry and tail-cuff methodology. Both methods revealed a consistent and 
significant elevation (+20-30 mmHg) in systolic, diastolic, and mean arterial blood pressure 
in GRAF3gt/gt mice relative to Wt mice indicating that GRAF3 expression in SMC is 
required for the maintenance of normal blood pressure (Fig. 3a, Supplementary Fig. S3a). 
Similar circadian variations were in blood pressure were apparent in both lines of mice (Fig. 
3b). Mice with one copy of the mutant allele (GRAFgt/t) in which vascular GRAF3 mRNA 
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levels were reduced by half also exhibited significant hypertension (+15 mmHg), indicating 
that there is a dose-dependent relationship between GRAF3 expression and basal blood 
pressure (Supplementary Fig. S3b). Remarkably, the hypertensive phenotype of GRAF3gt/gt 
mice was completely reversed within 90 min after injection of the Rho-kinase inhibitor 
fasudil (10mg/kg i.p.) which resulted in mean systolic pressures of 81.3 mmHg versus 79.2 
mmHg in Wt versus GRAF3gt/gt mice respectively, indicating that elevated RhoA signaling 
is a major mechanism by which GRAF3 deficiency induces high basal blood pressure. Since 
elevated RhoA activity is a critical mechanism for the effects of many GPCR-coupled 
contractile agonists14,16, we also measured blood pressure by intra-aortic catheterization in 
animals treated with AngII, ET-1, or PE. As shown in figure 3c, agonist-induced increases 
in systolic blood pressure were significantly enhanced in the GRAF3gt/gt mice and pre-
treatment with the ROCK inhibitor, Y27632 completely abrogated the elevated pressor 
responses strongly supporting increased RhoA activity in this model. Although the effects of 
GRAF3 depletion on the PE response were less robust, these data are consistent with 
previous studies suggesting that the pressor effects of PE are less Rho-dependent than AngII 
and ET-114,16.
Blood pressure is tightly controlled by an integrated signaling balance that involves multiple 
organs including the heart, brain, kidney, and vessel wall. Since the expression of GRAF3 in 
these organ systems was restricted to the vasculature, we surmised that the hypertensive 
phenotype in this model was likely due to a RhoA-dependent increase in myogenic tone. 
However, we first tested the possibility that more common defects in neurogenic or renal 
hemodynamics were involved. To evaluate sympathetic activity, we measured plasma and 
urine levels of metanephrine and normetanephrine, the stable metabolites of epinephrine and 
norepinephrine respectively. As shown in Supplementary Fig. S3c, we found no significant 
differences in circulating or excreted catecholamine levels between Wt and GRAF3gt/gt 
mice. Accordingly, we observed no significant differences in basal heart rate in GRAF3gt/gt 
and Wt mice (n=5/genotype, mean +/− s.e.m. of 643.5 +/− 36.5 and 666.7 +/− 18.7 
beats/min respectively). Moreover, the α1-adrenergic blocker, prazosin caused a similar 
reduction of blood pressure in Wt and GRAF3gt/gt mice, and unlike treatment with fasudil, 
did not normalize the high blood pressure caused by GRAF3 deficiency (Supplementary Fig. 
S3d); indicating that the elevated blood pressure in GRAF3gt/gt mice was not likely due to 
enhanced sympathetic stimulation. Kidney structure and function in GRAF3gt/gt mice was 
also normal as assessed by a panel of kidney functionality parameters and histological 
evaluation of periodic acid Schiff and hematoxylin and eosin- stained sections of the renal 
cortex (Supplementary Table S3, Supplementary Fig. S4a). Notably, urinary albumin (A) 
and creatinine (CR) levels and A/CR ratios were not significantly different between Wt and 
GRAF3gt/gt mice (Supplementary Fig. S4b). Thus, we conclude that neuro-renal dysfunction 
is not likely to play a causative role in the development of hypertension in this model. We 
next tested whether counter-regulatory mechanisms to maintain blood pressure in the face of 
elevated vessel tone were activated in GRAF3gt/gt mice. Modulation of angiotensin I-
converting enzyme (ACE) levels was an attractive candidate because ACE expression is 
known to be tightly linked to basal blood pressure. As shown in Supplementary Fig. S4c, we 
found a significant decrease in ACE protein levels in lungs (the organ in which ACE is most 
abundant) from GRAF3gt/gt mice when compared to Wt mice, indicating that negative 
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feedback mechanisms to limit AngII signaling are operative in the GRAF3gt/gt mice and that 
the elevated blood pressures observed could be due to a partially compensated increase in 
Rho-dependent vessel tone.
GRAF3 limits RhoA-dependent SMC contractility
To further test our hypothesis that GRAF3 depletion induced hypertension by stimulating 
RhoA-dependent SMC contractility we next tested the capacity of GRAF3 to stimulate the 
GTPase activity of RhoA and related small GTPases. To this end, we ectopically expressed 
full-length Myc-epitope tagged GRAF3 in COS cells and immunoprecipitated the enzyme 
using an anti-Myc Ab. Immunoprecipitates were combined with purified His-tagged RhoA, 
Cdc42, Rac1, and H-Ras and the extent of GTP hydrolysis was measured using a well-
characterized method to detect inorganic phosphate. As shown in Supplementary Fig. S5a, 
immune complexes containing Myc-GRAF3 exhibited a four-fold increase in GAP activity 
towards RhoA. GRAF3 also induced a modest increase in GAP activity towards Cdc42 but 
did not promote Rac1 or Ras GTP hydrolysis. We used several gain/loss of function 
experiments to confirm the ability of GRAF3 to function as a RhoA-GAP in vivo. As shown 
in figure 4a, ectopic expression of GRAF3 in primary vascular SMC markedly attenuated 
RhoA-dependent actin stress fiber and focal adhesion formation. Conversely, vascular SMC 
transfected with validated GRAF3 siRNAs exhibited a more contractile morphology that 
included more abundant focal adhesions increased actin-stress fibers, and elevated pMLC 
(Fig. 4b, c). A similar contractile phenotype was observed in vascular SMC isolated from 
GRAF3gt/gt mice compared to those isolated from control animals (Supplementary Fig. 
S5c). Importantly, direct measurements of RhoA activity by the GST-rhotekin precipitation 
assay revealed that activation of RhoA by the lipid agonist, sphingosine 1-phosphate was 
significantly elevated and prolonged in GRAF3-depleted SMC when compared to control 
siRNA-treated cells (Fig. 4d). Moreover, using a luminescence based assay to quantify the 
GTP bound form of RhoA, we found that RhoA activity was significantly increased in aortas 
from GRAF3gt/gt mice compared to those from Wt mice, validating GRAF3 as a bone fide 
GAP for RhoA in vivo (Fig 5a). Taken together, these results indicate that GRAF3 plays a 
major role in limiting RhoA activity in vascular SMC.
To provide additional evidence that the hypertensive phenotype observed in GRAF deficient 
mice is due to a RhoA dependent increase in vessel tone, we assessed vasoconstrictor 
responses in aortic segments isolated from Wt and GRAFgt/gt mice. Similar to our in vivo 
findings, the constrictor effects of AngII, ET-1 and PE were significantly enhanced in vessel 
segments from GRAFgt/gt mice and this enhancement was reversed by Rho kinase inhibition 
(Fig. 5c). Importantly, both aortic segments and peripheral resistance vessels from 
GRAF3gt/gt mice exhibited elevated levels of phosphorylated MLC relative to control mice 
(Fig. 5b, d), supporting the postulate that enhanced RhoA-induced myogenic tone is the 
main pathogenic factor underlying blood pressure elevation in GRAF3-depleted mice.
Discussion
Our results demonstrate for the first time that GRAF3 regulates blood pressure homeostasis. 
Activation of the small GTPase RhoA in vascular SMC has been implicated in the 
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development of vasoconstrictor-induced hypertension14,16, but until now, the extent that 
RhoA contributed to the maintenance of basal blood pressure was unknown and the 
mechanisms that limit RhoA activity in SMC were undetermined. The remarkable SMC-
selective expression pattern of this Rho-specific GAP when coupled with the ability of 
Rhokinase inhibition to normalize the hypertensive phenotype of GRAF3 deficient animals 
strongly supports a model in which GRAF3 plays a major role in regulating RhoA-mediated 
SMC contractility in resistance vessels. Importantly, our results also provide a mechanistic 
link for the hypertensive locus recently identified within the GRAF3 gene and highlight the 
need to identify the causal SNPs within this locus and to determine whether these SNPs 
affect GRAF3 expression in patient populations. Moreover, these findings support the 
exciting possibility that targeting the induction or activation of GRAF3 may provide a new 
therapeutic opportunity in the treatment of hypertension.
Methods
Reagents and Tissue Samples
The anti-Flag (M2), anti-vinculin and SMα-actin antibodies were purchased from Sigma as 
were the following chemicals: PE, ET-1, AngII, and prazosin. ACE and GAPDH antibodies 
were from Santa Cruz. The myosin light chain2 and phospho-myosin light chain2(Thr18/
ser19) antibodies were from Cell Signaling. Y27632 was purchased from Calbiochem and 
sphingosine-1-phosphate (S1P) was from Cayman Chemicals. SM-22 antibody was a 
generous gift from Mario Gimona. The anti-GRAF1 antibody was described in our previous 
publication,21 the GRAF2 antibody was a generous gift from Dr. Wen Xiong 24, and a 
GRAF3 Ab (referred herein as GRAF3Ab1) was purchased from Abnova. The myc-tagged 
GRAF3 human cDNA clone was purchased from Open Biosystems. GRAF1, GRAF2 
cDNAs were previously described21,24. Human tissue samples were obtained post-mortem 
during autopsy conducted at the University of North Carolina in compliance with current 
HIPAA rules and regulations.
Generation of GRAF3 polyclonal antibody
Amino acid sequences of human, mouse, and rat GRAF3 were aligned and the conserved 
sequence CLSTGRSRKPRGRYTP of GRAF3 was selected for antibody production. 
Purified peptides were obtained commercially (Invitrogen) and rabbit polyclonal antibodies 
were generated commercially by standard procedures (Cocalico Biologicals). Sera were 
screened for immunoreactivity and specificity by Western analysis of lysates generated from 
COS cells transfected with plasmids encoding human GRAF1, mouse GRAF2 or human 
GRAF3 (Supplementary Fig. S1).
Cell Culture and Transfections
Human coronary SMC (huCoSMC; Cambrex) and human aortic SMC (huAoSMC; 
Cambrex) were maintained in Clonectics SmGM media containing 5% FBS, insulin, hEGF, 
hFGF, and gentamicin and were used between passage 3 and 6. Primary aortic vascular 
SMC were isolated from Wistar rats (RAoSMC) or Wt or GRAF3gt/gt mice as described 25. 
In brief, thoracic aortas were stripped of the endothelial and adventitial layers by micro-
dissection. The SMC in the media were isolated by enzymatic digestion in buffer containing 
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trypsin and collagenase. Cells were maintained in Dulbecco's modified eagle medium with 
F12 supplemented with 10% fetal bovine serum and 0.5% penicillin/streptomycin and used 
from passage 8-16. Each of our preparations is routinely tested for expression of smooth 
muscle-specific markers (by immunohistochemistry) and the ability to drive smooth muscle 
specific expression of reporter constructs. Only the cell lines that are deemed at least 85% 
pure by these measurements are utilized for further experimentation. Cells were transfected 
with cDNA constructs using Trans-IT (Mirus) transfection reagents according to 
manufacturer's protocol. GRAF3 was depleted from primary aortic SMCs using short 
interfering RNA (siRNA) (Dharmacon) with the following sequences: sense, 5′-
GCCUGAUAGUGACUCCUAUtt; antisense, 5′-AUAGGAGUCACUAUCAGGCtc. Cells 
were transfected with gene-specific siRNA (100 nmol/L) or non targeted control (NTC) 
siRNA designed against green fluorescent protein using DharmaFECT reagent 1 for 72-96 
hr.
Generation and characterization of GRAF3-deficient mice
GRAF3 gene trap ES cells were developed by Genome Research Limited (Sanger Institute, 
SIGTR ES CE0477) and were distributed by the Mutant Mouse Regional Resource Center at 
the University of California, Davis. Chimeric mice were produced in house by injection of 
GRAF3+/gt ES cells into the blastocoel cavity of mouse blastocysts by standard procedures. 
The GRAF3gt strain was established using three independent chimeras that demonstrated 
germ line transmission when bred to wild-type C57bl6 mice. Homozygous GRAF3gt/gt mice 
were generated by crossing F1 GRAF3gt/+ mice and all experiments were performed using 
age, sex, and littermate genetic controls. For timed pregnancies, day 0.5 of gestation (E0.5) 
was noon of the day of vaginal plug observation. Genotyping was performed using DNA 
isolated from tail biopsies using either LacZ (5’-
GCATCGAGCTGGGTAATAAGCGTTGGCAAT; 3’-
GACACCAGACCAACTGGTAATGGTAGCGAC) or locus-specific primers (5’-
TTCGTTGAGACAACTGCACACC; 3’-CCCTTCACACTTTGCTCTCTTAGC). Surgeons 
were not privy to genotype information. Animal husbandry was provided by staff within the 
University of North Carolina Division of Laboratory and Animal Medicine and all animal 
procedures were approved by our accredited American Association for Accreditation of 
Laboratory Animal Care committee.
Blood pressure measurements
Conscious blood pressure was measured in male mice aged 12-16 weeks using either radio-
telemetry or a tail cuff detection system (Iworx, LabScribe software). For radiotelemetry, 
implantable mouse BP transmitters (TA11PA-C10, Data Sciences International) were used 
to record arterial pressure in conscious and freely moving mice (5-6 month old males 
weighing 30-35g). In brief, the mice were anesthetized with 2% isoflurane and the telemetry 
catheter was inserted into the left carotid artery of the mouse and the catheter tip was 
advanced into the thoracic aorta. The catheter was fixed in the left carotid artery and the 
transmitter was inserted subcutaneously on the backs of mice. Mice were allowed 7 days of 
recovery following transmitter implantation and were housed individually in a standard 
polypropylene cage placed on a radio receiver. Mice were maintained in a 12:12-h light-dark 
cycle. All blood pressure parameters were telemetrically recorded and stored with the 
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Dataquest ART data acquisition system (Data Sciences International). 5 minute recordings 
were collected every 30 min. and data was analyzed using Excel software.
For the tail cuff measurements, 3-4 month old male mice were subjected to 20 
measurements over a period of 20 minutes taken every day (between 8 and 10 AM) for 6 
consecutive days as previously described 26. Data is presented as an average of 
measurements on the final day. To measure unconscious blood pressure, 6 month old male 
mice were anaesthetized with isofluorane, and the right carotid artery was exposed. A 
pressure transducer (Millar) was inserted through the carotid into the aorta to measure aortic 
pressure. Vasoconstrictors were administered through a catheter inserted into the left jugular 
vein. Between doses of vasoactive agents, each animal was allowed to recover its blood 
pressure to resting levels26. In some experiments, Rho kinase inhibitor (3 or 10 mg/kg) was 
injected i.p and pressures were monitored 30 minutes after dosing.
Kidney function measurements
50 μl of urine was collected from 6 month old male GRAF3gt/gt and genetic control mice 
and urinary albumin was determined using an Albuwell-M kit (Exocell Inc, Philadelphia, 
PA). Spot urine creatinine level was measured on an automated chemical analyzer, VT350 
from Ortho Clinical Diagnostics. Metanephrine and normetanephrine levels in plasma and 
urine were measured by ELISA (Metcombi Plasma ELISA, IBL) as per manufacturer's 
instructions. Additional kidney panel parameters were analyzed in 100 μl blood samples 
collected from GRAF3gt/gt and genetic control mice using a VetScan Blood Chemistry 
Analyzer as per manufacturer's instructions.
Myography
Two 3 mm aortic segments were collected per mouse (6 month old males), cleaned from 
adventitia, and placed in ice cold Krebs buffer (in mmol/L; 120 NaCl, 25 NaHCO3, 11 
glucose, 1.8 CaCl2, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4). The aorta segments were mounted 
in a Radnoti 4-unit organ bath system (Radnoti Glass Technology Inc.) in 20 ml buffer 
reservoirs containing Krebs (37 degrees C) aerated constantly with 95% O2 + 5% CO2 gas 
mixture. After a 45-60 min. stabilization, the baseline tension of the rings was adjusted to 
700 mg. All rings were constricted with 124 mM KCl at the end of the experiment and the 
degree of contraction to indicated agonist was expressed as a percentage of the maximum 
constriction induced by KCl.
LacZ staining and Immunohistochemistry
Tissues were processed for LacZ staining using previously published methods 29. Briefly, 
tissues were rinsed in 1× phosphate-buffered saline (PBS) and fixed in 4% 
paraformaldehyde (PFA)-PBS for 20 min at room temperature. After three 10-min washes in 
embryo wash buffer (0.1 M phosphate buffer [pH 7.3], 0.1% sodium deoxycholate, 0.02% 
NP-40, 0.05% bovine serum albumin [Sigma]), tissues were incubated 30 min to overnight 
at RT in X-Gal staining solution (wash buffer containing 1 mg of X-Gal/ml [Sigma], 5 mM 
ferrocyanide, and 5 mM ferricyanide). Tissues were then post fixed in the appropriate 
fixative, cleared and imaged. For general tissue immunohistochemistry, tissue from mouse 
pups or patients were harvested, and frozen in OCT or paraffin-embedded. Paraffin sections 
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were processed for H& E staining or Periodic acid Schiff (PAS) using standardized kits 
(Sigma). Frozen tissues were sectioned and post-fixed with paraformaldehyde or MeOH 
using standard conditions and processed for immunohistochemical staining. In brief, 
sections were permeabilized, blocked, and incubated with primary antibodies overnight 
using the following concentrations: anti-GRAF3 Abs (1: 200), α-SMA (1: 200), PE-CAM 
Ab (1: 200), β-GAL (1: 200). Cells were processed for immunocytochemistry using 
previously published methods 25. In brief, cells were fixed with 4% paraformaldehyde, 
permeabilized with 4% Triton X-100 in PBS, incubated with primary antibodies (1:200) for 
1 hour. After washing with PBS, slides were incubated for 1 hour with TRITC or FITC-
conjugated goat or rabbit anti-mouse antibodies (2μg/ml) or Alexa Fluor488- or 555-
conjugated phalloidin and DAPI to detect filamentous actin and nuclei respectively.
GAP Assays
COS cells transfected with vector control or Myc-tagged human GRAF3 were lysed in 
modified RIPA buffer and GRAF3 was immunoprecipitated using a Myc-eptitope specific 
Ab (2 μg/mg lysate). Immunoprecipitates were combined and re-suspended in GAP assay 
buffer and divided accordingly to assess GAP activity towards purified His-tagged RhoA, 
Rac1, Cdc42, or H-Ras per 500 μg of lysate using the colorimetric-based GTPase activation 
assay (BK105, Cytoskeleton) as per manufacturer's instructions. One-half of the amount 
used in the GAP assay was removed and analyzed by immunoblotting to verify the presence 
of GRAF3 in the experimental but not the negative control samples.
Rho Activity Assays in cultured cells
Rat aortic SMC were serum starved overnight prior to treatment with S1P for indicated 
times. Cell lysates were rotated with 40 μg of a GST-rhotekin Rho binding domain fusion 
protein immobilized to glutathione-Sepharose 4B beads (Amersham Biosciences) for 15 min 
at 4 °C in binding buffer (50 mM Tris, pH 7.6, 500 mM NaCl, 0.1% SDS, 0.5% 
deoxycholate, 1% Triton X-100, 0.5 mM MgCl2)23. Beads were precipitated and washed 
three times (50 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2) and 
resuspended in 2× Laemmli buffer. Proteins were separated on a 15% SDS-PAGE and 
transferred to 0.2 μm polyvinylidene difluoride (Bio-Rad). After blocking in 3% bovine 
serum albumin/TBST (20 mM Tris-HCl, 500 mM NaCl, 0.05% Tween-20, pH 7.4) for 
30min at room temperature, blots were probed with 2 μg/ml anti-RhoA (26C4) (Santa Cruz 
Biotechnology) overnight at 4 °C. Loading controls (typically 10%) are taken from each 
lysate sample prior to pull downs.
RhoA activity assays in vessel segments
2 cm segments from the descending aorta were collected from Wt and GRAF3gt/gt mice (6 
month old male and female). The adventitia was rapidly stripped and segments were 
immediately snap frozen in liquid nitrogen for use in the G-LISA luminescence-based RhoA 
specific activation assay (BK121, Cytoskeleton). In brief, frozen aortic segments were 
crushed using a liquid nitrogen-cooled mortar and pestle and immediately transferred to 200 
μl ice cold lysis buffer containing protease inhibitors (supplied by the manufacturer) 
followed by sonication (3 x 1 sec pulses at 40% power; Sonics VibraCell). Lysates were 
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clarified by centrifugation (2 min at 4 degrees C) and the level of RhoA activity was 
measured in 20μg samples as per the manufacturer's instructions (Cytoskeleton).
Western Blotting
To examine protein levels, lysates from cells or tissues were prepared by lysing in a 
modified RIPA buffer with protease and phosphatase inhibitors25. Protein concentration was 
determined by using a colorimetric BCA assay (Pierce). Lysates were electrophoresed on 
10-15% SDS-polyacrylamide gel, transferred to nitrocellulose, and immunoblotted with 
specific antibodies at the following concentrations SM alpha-actin (1:2000), SM-22 
(1:1000), Calponin (1:2000), alpha-tubulin (1:2000). Blots were washed in TBST (TBS plus 
0.05% Triton-X), followed by incubation with either horse-radish peroxidase conjugated- 
rabbit anti-mouse antibody or - Protein A sepharose (Amersham) at a 1/2000 dilution. Blots 
were visualized after incubation with chemiluminscence reagents (ECL, Amersham).
Semi Quantitative RT-PCR
Cells or organs harvested from mice were homogenized, and RNA was extracted using 
Zymo or Qiagen RNA isolation kit. Semi quantitative RT-PCR was performed with the 
following primers: Human SM α-actin 5’- TAAAGCTTCCCAGACTTCCGC, 3’-
TGTCCCATTCCCACCATCAC;
Human SM22 5’- GTGCATTTCAGGCAGGCTCTC, 3’- 
GCACTATGATCCACTCCACCA;
Human Calponin 5’- AACAACTTCATGGACGGCCT, 3’- 
TCTCCAGCTGGTGCCAATTT;
Mouse Myosin Heavy Chain 5’-GTTCATTCGCATCAACTTCG, 3’-
CGGCGAGCAGGTAGTAGAAG;
Mouse Calponin 5’-CTCTGCTTTGCCAGAGCCCCC, 3’-
TGACGCCGTGTACCGTAGGC;
Mouse SM α-actin 5’-CGCTGTCAGGAACCCTGAGA, 3’-
CGAAGCCGGCCTTACAGAG;
GRAF3 5’-CTGCCCACTCTGGAGTTCAGCG, 3’-GCTGCACCGATCTGTTCTTTTCG; 
GAPDH 5’-ATGGGTGTGAACCACGAGAA, 3’-GGCATGGACTGTGGTCATGA as 
described previously 30.
Statistical Analysis
All data represent at least 3 separate experiments presented as means±SEM. Means were 
compared by Student's t test or ANOVA (where indicated) and statistical significant is 
reported as p values. All other data, including Western blot analysis and RT-PCR, are 
representative of at least 3 individual experiments and band intensities were quantified using 
Image J software. Sample sizes were chosen based on an extensive literature search and 
standard exclusion criterion of 2-standard deviations from the mean were applied.
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Figure 1. GRAF3 is expressed in a smooth muscle-restricted fashion
Tissues from Wt mice (2-3 wk old) or human (2yr) were frozen in OCT, sectioned and 
stained with a specific GRAF3 antibody (red; also see Supplementary Fig. S1 and 
Supplementary Fig. S2d, e). Some samples were co-stained with PECAM antibody (green). 
DAPI is shown in blue. a, arteriole/artery; b, bronchi; v, vein; adv., adventitia; epi, epithelial 
layer; mus, smooth muscle layer. Note strong expression of GRAF3 throughout the media of 
human carotid artery and in the microvessels within the adventitia. Scale bars are 100 
microns for mouse tissue and 550 microns for human tissues.
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Figure 2. Development of GRAF3 hypomorphic mice
a, Schematic of gene trap insertion site in the SIGTR CE0477 ES clone. 5’ RACE revealed 
the gene trap cassette was located in intron 3 (see Supplemental Supplementary Table S1) 
and this locus was verified and further refined using a targeted PCR approach that revealed 
the site of integration between Chromosome 9: 9,082,984-9,083,121 (reverse strand). b, RT-
PCR analysis of GRAF3 (exon 1-4) and GAPDH mRNA levels in tissues from Wt and 
GRAF3gt/gt mice (quantification shown graphically below; mean +/− s.e.m., n=3/genotype). 
Similar results were found using primers to target downstream exons (see Supplementary 
Fig. S2b). c, GRAF3 expression pattern revealed by whole mount Lac Z staining (blue; scale 
bars are 1.5 mm) or by dual immunohistochemical staining for β-GAL (green; scale bar is 10 
microns), PECAM (red), (DAPI, blue) in frozen sections (coronary vessel, top-middle) from 
GRAF3t/gt mice . Vessel-restricted LacZ staining was also evident in brain (See 
Supplementary Fig. S2f). No significant LacZ staining or β-GAL immunofluorescence was 
observed in tissues from Wt mice. mes, mesenteric.
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Figure 3. GRAF3gt/gt mice exhibit Rho-kinase dependent hypertension and elevated pressor 
responses
a,b, Blood pressures in Wt and GRAF3gt/gt mice were recorded by radiotelemetry over a 24 
hr period. Measurements from 5 min recordings taken every 30 min were averaged (panel a) 
or plotted as hourly recordings (panel b) (n=5/genotype). Similar values were obtained by 
standard tail cuff recordings of a separate group of Wt and GRAF3gt/gt mice (see 
Supplementary Fig. S3a) c, Acute arterial pressure was monitored (n=5/genotype) using a 
Millar catheter prior to and following i.v. injection of indicated vasoconstrictive agent with 
or without pre-treatment of Y27632 (10 mg/kg i.p.). All values are expressed as means +/− 
s.e.m. p values (Student's t-test) are expressed as : * p<0.05; ** p<0.01;*** p<0.001.
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Figure 4. GRAF3 depletion in cultured SMC promotes Rho activity
a, Ectopic expression of myc-GRAF3 (arrow, left; blue, right) in rat aortic SMC (RAoSMC) 
induced marked clearing of actin stress fibers as assessed by phalloidin staining (white, left 
or green, right) and focal adhesions as marked by vinculin (white, left or red, right). b, 
Levels of GRAF3 and GAPDH mRNA in control (Csi) and GRAF3 (G3) si-treated 
RAoSMC. Data are representative of 7 separate experiments c, GRAF3 si-treated RAoSMC 
exhibited a more contractile morphology (more abundant vinculin-labeled focal adhesions 
and phalloidin-labeled stress fibers) and elevated phospho-MLC (pMLC) when compared 
with control si- (Csi) treated cells. d, GRAF3-si and Csi-treated RAoSMC were stimulated 
with S1P and active (GTP-bound) RhoA was precipitated with GST-rhotekin beads and 
assessed by immunoblotting (top panel). Densitometric analysis of 3 separate experiments is 
presented as mean +/− s.e.m. (bottom panel). p values (Student's t-test) are expressed as : † 
p<0.1; * p<0.05; ** p<0.01; ***p<0.001.
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Figure 5. GRAF3-depleted vessels exhibit elevated Rho activity and enhanced Rho-dependent 
contractility
a, ELISA-based RhoA activity assays were performed on aortic lysates isolated from 6 
month old Wt and GRAF3gt/gt mice (n=6/genotype; mean +/− s.e.m.; p values (Student's t-
test) are expressed as * p<0.05). b, Densitometric quantification of Western blots probed for 
total- and pMLC in aortas from 6 month old GRAF3gt/gt versus Wt mice (n=7; mean +/− 
s.e.m.; p values (Student's t-test) are expressed as * p<0.05). c, Dose response of indicated 
agonist on contraction of aortic segments isolated from Wt and GRAF3gt/gt mice (n=5/
genotype). Values (mean +/− s.e.m.) are expressed as percentage of KCl (124 mM)-induced 
contraction (no significant difference was observed in maximal contraction of GRAFgt/gt 
segments compared to Wt vessels). p values (Student's t-test) are expressed as : † p<0.1; * 
p<0.05; ** p<0.01; ***p<0.001. d, Immunohistochemistry reveals elevated pMLC levels in 
vascular SMC in gastric resistance arterioles (arrowheads) and in visceral stomach smooth 
muscle (asterisk) from GRAF3gt/gt mice. Images are representative of 4 animals/genotype. 
Scale bars are 50 microns.
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